UMC7300 Ultrasonic Coating System: Enabling R&D of Paclitaxel-Coated Balloon Catheters and Limus-Eluting Coronary Stents
Developing drug-coated cardiovascular devices requires careful coordination between formulation science, device geometry and coating-process control. An Ultrasonic Balloon Catheter Coating System can provide a laboratory platform for exploring how coating formulations are deposited on delicate medical-device surfaces. The UMC7300 is intended for research and development, process development, optimisation and prototype production—not as a substitute for device-specific validation or regulatory qualification.
For teams investigating drug-coated balloons and drug-eluting coronary stents, the work may involve different drug families and distinct substrate geometries. Paclitaxel-based formulations are commonly investigated for balloon-catheter coatings, while limus-based formulations may be studied for coronary stent coatings. The appropriate formulation, solvent system and process window must be established for each device and intended use.
Why use an ultrasonic coating platform in cardiovascular R&D?
Researchers need a repeatable way to investigate the relationship between formulation properties and coating outcomes. An ultrasonic coating approach can support controlled atomisation and deposition studies while teams examine how process settings, fixture design and part handling affect coating coverage. The value of a lab-scale system is the ability to structure experiments, record conditions and compare samples—not an assumption that one set of parameters works for every device.
Research with balloon-catheter surfaces
Balloon coatings present challenges associated with curved, flexible surfaces, folds, transitions and small target areas. During early development, researchers can assess whether a proposed formulation wets the substrate appropriately, where material accumulates, and whether coating distribution remains acceptable after the balloon is handled or folded. Paclitaxel-based coatings require formulation-specific evaluation, including drug distribution and any relevant residual-solvent or adhesion assessments.
Research with coronary stents
Stents have small features, edges, struts and open spaces that make coating coverage and unwanted bridging important subjects for investigation. When exploring limus-based formulations, development teams may compare spray paths, part orientation, formulation delivery and drying conditions. Microscopy and suitable analytical methods should be used to assess the coating rather than relying on visual appearance alone.
Where the UMC7300 fits in a development workflow
- Define the study: document the device substrate, formulation objective, target areas and acceptance criteria.
- Prepare a controlled formulation: record composition, preparation history and relevant material properties under the laboratory’s approved procedures.
- Run screening trials: vary selected process factors systematically and label every sample.
- Characterise coated samples: examine coverage, uniformity, defects and drug-related attributes using methods suitable for the project.
- Refine and document: retain process records and repeat promising conditions to assess reproducibility.
Cheersonic’s ultrasonic drug balloon coating machine page provides product-related information. For broader context on the technology, see ultrasonic atomizing coating.
What should a research team evaluate?
Build the study around measurable, device-specific questions. Depending on the project, these may include coating distribution, local accumulation, drug loading, adhesion, morphology, particulate generation, drying behaviour and coating integrity after relevant handling steps. Not every attribute applies to every device, and test methods should be selected by qualified engineers and scientists. Any eventual manufacturing process must be separately assessed against the device’s quality system, applicable standards and regulatory requirements.
Frequently asked questions
1. Can the UMC7300 be used for both balloon catheters and coronary stents?
It is positioned for R&D and prototype work involving drug-coated cardiovascular-device surfaces. Suitability for a specific balloon or stent geometry should be confirmed through a project review and sample-coating evaluation.
2. Does one process recipe work for paclitaxel and limus formulations?
No universal recipe should be assumed. Formulations can differ in solubility, viscosity, surface interaction and drying behaviour, so each formulation and substrate combination needs its own development work.
3. Does a successful laboratory coating prove clinical performance?
No. A coating trial is only one part of development. Safety, performance, stability, biocompatibility, sterilisation compatibility and regulatory evidence require separate, appropriate evaluations.
4. What information should we prepare before a sample test?
Useful inputs include the device type and dimensions, substrate material, target coating area, formulation information that can be safely shared, project objectives and the attributes you want to evaluate.
Discuss your medical-device coating project
Qualified medical-device manufacturers, R&D teams and production engineers are welcome to contact Cheersonic to discuss a coating project and arrange a sample coating test. Please email market2@cheersonic.com with a brief description of your device, research goals and evaluation needs.
